{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments, at least 4 weeks apart: white blood cell (WBC) count \\< 10 × 109/L; platelet \\< 450 × 109/L; basophils \\< 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes \\< 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data, all merged by patient and date.","groups":[{"description":"1 year to \\< 10 years pediatric patients","id":"OG000","title":"Group 1"},{"description":"\\>= 10 years to \\<18 years pediatric patients","id":"OG001","title":"Group 2"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.","reportingStatus":"POSTED","timeFrame":"minimum of 12 cycles (28 days per cycle)","title":"Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)","type":"SECONDARY","unitOfMeasure":"Participants"}